UNSPSC 51321808: Fenofibrate

This classification denotes an anti-lipidemic agent with the molecular formula C20H21ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U202363UOS, chemically known as propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester but generally known as fenofibrate, which bears US NIH Compound Identifier 3339. European Medicines Agency schedules Fenofibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07576MIG.

UNSPSC 51321808 Fenofibrate, a Commodity code, represents pharmaceutical products state and local governments procure through emergency medical services, health and human services departments, and cooperative purchasing alliances. The recent solicitations show state and local buyers acquiring generic multi-source pharmaceuticals and emergency medications—labetalol, epinephrine, adenosine, and diltiazem among them—through sealed competitive bids, requests for proposal, and cooperative purchasing vehicles. Issuing bodies include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. The work involves suppliers meeting cGMP and FDA compliance, maintaining expiration-date and shelf-life requirements, arranging rapid fulfillment and replacement protocols, and submitting comprehensive product documentation including NDC codes, Safety Data Sheets, and accessibility conformance reports.

The code shows recent activity across Florida, Texas, and Minnesota, with multistate cooperative purchasing extending reach to Oregon and other participating jurisdictions. The City of Tampa Fire Rescue issued IFB 26P00188 for Advanced Life Support Medications with a $40,000 estimated contract value and April 8, 2026 response deadline, applying a 5 percent bid discount for Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 due date, two-year contract term, and multi-award structure across three authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs, signaling future procurement development in pharmaceutical supply chain innovation.